Edition:
United States

Eisai Co Ltd (4523.T)

4523.T on Tokyo Stock Exchange

6,376JPY
19 Apr 2019
Change (% chg)

¥11 (+0.17%)
Prev Close
¥6,365
Open
¥6,438
Day's High
¥6,462
Day's Low
¥6,367
Volume
530,700
Avg. Vol
1,090,833
52-wk High
¥11,490
52-wk Low
¥6,040

About

Eisai Co., Ltd. is engaged in the research and development, manufacture, sale and import and export of pharmaceuticals. The Company's business segments include pharmaceutical segment and other segment. The pharmaceutical segment is engaged in the research, develop, manufacture and sale of pharmaceuticals for medical use, generic... (more)

Overall

Beta: 0.68
Market Cap(Mil.): ¥1,746,483.00
Shares Outstanding(Mil.): 296.57
Dividend: 80.00
Yield (%): 2.55

Financials

  4523.T Industry Sector
P/E (TTM): 57.32 29.30 32.55
EPS (TTM): 102.73 -- --
ROI: 4.05 14.23 13.83
ROE: 5.24 15.46 15.25

Biogen announces $5 billion buyback days after shelving Alzheimer's trials

Biogen Inc said on Monday it would buy back shares worth $5 billion, days after its stock slumped on the drugmaker's announcement to end two Alzheimer's disease trials.

Mar 25 2019

Biogen announces $5 bln buyback days after shelving Alzheimer's trials

March 25 Biogen Inc said on Monday it would buy back shares worth $5 billion, days after its stock slumped on the drugmaker's announcement to end two Alzheimer's disease trials.

Mar 25 2019

Eisai starts phase 3 trials for second Alzheimer's drug after first's failure

TOKYO Eisai Co Ltd on Friday said it has begun phase 3 clinical trials of Alzheimer's treatment BAN2401, a day after the Japanese drugmaker and U.S. partner Biogen Inc scrapped trials for another Alzheimer's drug, aducanumab.

Mar 22 2019

Nikkei falls as financials drag; Eisai indicated to dive

TOKYO, March 22 Japan's Nikkei fell in choppy trade on Friday as financial stocks languished, reflecting more cautious U.S. monetary policy, while the drug sector tumbled after Eisai and Biogen said they will end their Alzheimer's drug trials.

Mar 21 2019

Biogen scraps two Alzheimer drug trials, wipes $18 billion from market value

CHICAGO/TOKYO Biogen Inc and partner Eisai Co Ltd are ending two late-stage trials of their experimental Alzheimer's disease drug aducanumab, a major setback in the quest to find a treatment for the mind-wasting disease and a blow to Biogen, which lost more than $18 billion of its value on Thursday. | Video

Mar 21 2019

UPDATE 5-Biogen scraps two Alzheimer drug trials, wipes $18 bln from market value

CHICAGO/TOKYO, March 21 Biogen Inc and partner Eisai Co Ltd are ending two late-stage trials of their experimental Alzheimer's disease drug aducanumab, a major setback in the quest to find a treatment for the mind-wasting disease and a blow to Biogen, which lost more than $18 billion of its value on Thursday.

Mar 21 2019

UPDATE 4-Biogen scraps two Alzheimer drug trials, wipes $18 bln from market value

* Analysts question Biogen growth prospects (Recasts first paragraph, adds details; updates shares)

Mar 21 2019

US STOCKS-Wall St gains as tech boost offsets bank losses after Fed stance

* Indexes up: Dow 0.37 pct, S&P 0.47 pct, Nasdaq 0.71 pct (Changes comment, updates prices)

Mar 21 2019

US STOCKS-Wall St edges higher as tech boost counters losses in bank stocks

* Indexes up: Dow 0.09 pct, S&P 0.12 pct, Nasdaq 0.35 pct (Updates to open)

Mar 21 2019

US STOCKS-Wall St set for lower open after Fed's abrupt dovish turn

* Futures down: Dow 0.39 pct, S&P 0.38 pct, Nasdaq 0.45 pct (Adds comments, background, updates prices)

Mar 21 2019

Earnings vs. Estimates